Department of Cardiovascular Medicine, Minzu Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
Department of Obstetrics and Gynecology, Minzu Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
Anatol J Cardiol. 2022 May;26(5):366-372. doi: 10.5152/AnatolJCardiol.2021.276.
Hypertension is a vital risk factor for heart failure, while cardiac rehabilita-tion can effectively improve cardiac function of heart failure patients. This study aimed to determine the impact of cardiac rehabilitation on microRNA-423-5p in hypertensive patients with heart failure with a moderately reduced ejection fraction.
Sixty hypertensive patients with heart failure with a moderately reduced ejec-tion fraction were randomly divided into cardiac rehabilitation group and positive control group with 30 cases per group, while 30 hypertensive patients without heart failure were recruited as negative control group. The cardiac rehabilitation group and positive control group were treated with 1-month cardiac rehabilitation combined with the routine treat-ment and routine treatment only, respectively. The New York Heart Association classi-fication, 6-minute walking test, and color Doppler echocardiography were adopted to detect cardiac function. Meanwhile, the expression of microRNA-423-5p and N-terminal pro-B-type natriuretic peptide was determined via Real-Time Fluorescence Quantitative PCR and electrochemiluminescence immunoassay. The diagnostic potential of microR- 423-5p and N-terminal pro-B-type natriuretic peptide was assessed by ROC curve analy- sis and multivariate linear regression model.
Patients in cardiac rehabilitation group displayed significantly lower expression of microR-423-5p and better results of New York Heart Association classification, 6-min-ute walking test, and color Doppler echocardiography than those in positive controlgroup (P < .05). ROC analysis showed that microR-423-5p (AUC = 0.785; 95% CI: 0.686- 0.865; sensitivity = 73.33%; specificity = 73.33%) had better specificity and accuracy thanN-terminal pro-B-type natriuretic peptide (AUC=0.721; 95% CI: 0.617-0.811; sensitiv- ity = 81.67%; specificity = 63.33%).
MicroR-423-5p was implicated in left ventricular hypertrophy and might be a potential biomarker for assessing the therapeutic effect of cardiac rehabilitation on hypertensive patients with heart failure with a moderately reduced ejection fraction.
高血压是心力衰竭的一个重要危险因素,而心脏康复可以有效改善心力衰竭患者的心脏功能。本研究旨在探讨心脏康复对射血分数中度降低的高血压合并心力衰竭患者 microRNA-423-5p 的影响。
将 60 例射血分数中度降低的高血压合并心力衰竭患者随机分为心脏康复组和阳性对照组,每组 30 例,另选取 30 例高血压不合并心力衰竭患者作为阴性对照组。心脏康复组和阳性对照组分别给予 1 个月的心脏康复治疗联合常规治疗和单纯常规治疗。采用纽约心脏协会心功能分级、6 分钟步行试验和彩色多普勒超声心动图检测心功能,实时荧光定量 PCR 和电化学发光免疫分析法检测 microRNA-423-5p 和 N 末端脑钠肽前体的表达。采用 ROC 曲线分析和多元线性回归模型评估 microRNA-423-5p 和 N 末端脑钠肽前体的诊断价值。
心脏康复组患者的 microRNA-423-5p 表达水平显著降低,纽约心脏协会心功能分级、6 分钟步行试验和彩色多普勒超声心动图的结果显著改善,优于阳性对照组(P<0.05)。ROC 分析显示,microRNA-423-5p(AUC=0.785;95%CI:0.686-0.865;敏感性=73.33%;特异性=73.33%)的特异性和准确性优于 N 末端脑钠肽前体(AUC=0.721;95%CI:0.617-0.811;敏感性=81.67%;特异性=63.33%)。
microRNA-423-5p 参与左心室肥厚,可能是评估心脏康复对射血分数中度降低的高血压合并心力衰竭患者治疗效果的潜在生物标志物。